Modern approaches to therapeutic vaccination as treatment for Type 1 respiratory hypersensitivity (allergy) treatment

References

• Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int. Arch. Allergy Immunol. 135(1), 73–82 (2004).
   PubMed Web of Science ®Google Scholar
• Braun-Fahrlander C, Gassner M, Grize I et al. Prevalence of hay fever and allergic sensitization in farmer’s children and their peers living in the same rural community. SCARPOL team. Swiss Study on Childhood Allergy and Respiratory Symptoms with Respect to Air pollution. Allergy 29(1), 28–34 (2002).
   Google Scholar
• Martinez FD. The coming-of-age of the hygiene hypothesis. Respiratory Research. 2, 129–132 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson CC, Ownby DR, Alford SH et al. Antibiotic exposure in early infancy and risk for childhood atopy. J. Allergy Clin. Immunol. 115(6), 1218–1224 (2005).
   PubMed Web of Science ®Google Scholar
• D’Amato G, Liccardi G, D’Amato M. Environmental risk factors (outdoor air pollution and climatic changes) and increased trend of respiratory allergy. J. Investig. Allergol. Clin. Immunol. 10(3), 123–128 (2000).
   PubMed Web of Science ®Google Scholar
• Midoro-Horiuti T, Brooks EG, Goldblum RM. Pathogenesis-related proteins as plant allergens. Ann. Allergy Asthma Immunol. 87(4), 261–271 (2001).
   PubMed Web of Science ®Google Scholar
• Spergel JM. Atopic march: link to upper airways. Curr. Opin. Allergy Clin. Immunol. 5(1), 17–21 (2005).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases; an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35(4), 408–416 (2005).
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109(2), 251–256 (2002).
   PubMed Web of Science ®Google Scholar
• Van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T-cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163(5), 2944–2952 (1999).
   PubMed Web of Science ®Google Scholar
• Moverare R. Immunological mechanisms of specific immunotherapy with pollen vaccines; implications for diagnostics and the development of improved vaccination strategies. Exp. Rev. Vaccines. 2(1), 85–97 (2003).
   PubMedGoogle Scholar
• Kepley CL, Cambier JC, Morel PA et al. Negative regulation of FcepsilonR1 signaling by FcγRII costimulation in human blood basophils. J. Allergy Clin. Immunol. 106(2), 337–348 (2000).
   PubMed Web of Science ®Google Scholar
• Stuck BA, Schneider-Gene S, Schafer D, Klimek L, Hormann K. Short-term preseasonal immunotherapy with birch pollen allergoids plus monophosphoryl lipid A (MPL): Influence on cytokine production of peripheral T-cells in patients with allergic rhinitis. Allergy Clin Immunol. Int. 16(2), 60–64 (2004).
   Google Scholar
• Jutel M, Akdis M, Budak F et al. IL-10 and TGF-β co-operate in the regulatory T-cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33(5), 12051214 (2003).
   PubMed Web of Science ®Google Scholar
• Sabroe I, Parker LC, Wilson MK, Dower SK. Toll-like receptors; their role in allergy and non-allergic inflammatory diseases. Clin. Exp. Allergy 32(7), 984–989 (2002).
   PubMed Web of Science ®Google Scholar
• Lucas M, Stuart LM Savill J, Lacy-Hulbert A. Apoptic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J. Immunol. 17(5), 2610–2615 (2003).
   Google Scholar
• Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468–475 (1999).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey RF, Malling H-J. WHO Position Paper Allergen Immunotherapy; therapeutic vaccines for allergic disease. Allergy 53(44 Suppl.), 1–42 (1998)
   Web of Science ®Google Scholar
• Wheeler AW, Woroniecki SR. Immunological adjuvants in allergy vaccines: Past. present and future. Allergology International 50, 295–301 (2001).
   Google Scholar
• Marsh DG, Lichtenstein LM, Campbell DH. Studies on ‘allergoids’ prepared from naturally occurring allergens. 1. Assay of allergenicity and antigenicity of formalinized rye group1 component. Immunology 18(5), 705–722 (1970).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Proll S, Urban E, Woroniecki SR. Single-course specific immunotherapy with mixed pollen allergoids: results of a multi-centre study. Allergologia et Immunopathologia. 31, 77–82 (2003).
   PubMedGoogle Scholar
• Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60(1), 4–12 (2005)
   PubMed Web of Science ®Google Scholar
• Kay AB, Larche M. Allergen immunotherapy with cat allergen peptides. Springer Semin. Immunopathol. 25(3–4), 391–399 (2004).
   Google Scholar
• Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116(2), 347–354 (2005).
   PubMed Web of Science ®Google Scholar
• Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113(6), 1144–1151 (2004).
   PubMed Web of Science ®Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experience and new directions. Pharm. Biotechnol. 6, 495–524 (1995).
   PubMedGoogle Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56(6), 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun. 71(5), 2498–2507 (2003).
   PubMed Web of Science ®Google Scholar
• Jutel M, Jaeger L, Meyer H, Cromwell O, Narkus A. Specific immunotherapy with recombinant grass pollen allergens is clinically efficacious. EAACI Congress, Amsterdam, The Netherlands (Abstract 450), 137, (2004).
   Google Scholar
• Niedberger V, Valenta R. Recombinant allergens for immunotherapy. Where do we stand? Curr. Opin. Allergy Clin. Immunol. 4(6), 549–554 (2004).
   PubMed Web of Science ®Google Scholar
• Holm J, Gajhede M, Ferraras M et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J. Immunol. 173(8), 5258–5267 (2004).
   PubMed Web of Science ®Google Scholar
• Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 17(1), 37–52 (2000).
   PubMed Web of Science ®Google Scholar
• Moran DM, Wheeler AW. Chemical Modification of crude timothy grass pollen extract. 1. Antigenicity and immunogenicity changes following amino group modification. Int. Archs. Allergy. Appl. Immun. 50, 693–708 (1976).
   PubMedGoogle Scholar